Sage Journals: Discover world-class research

Abstract

Objective:

To evaluate treatment patterns for ADHD in Sweden.

Method:

Observational retrospective study of patients with ADHD from the Swedish National Patient Register and Prescribed Drug Register, 2018 to 2021. Cross-sectional analyses included incidence, prevalence, and psychiatric comorbidities. Longitudinal analyses (newly diagnosed patients) included medication, treatment lines, duration, time-to-treatment initiation, and switching.

Results:

Of 243,790 patients, 84.5% received an ADHD medication. Psychiatric comorbidities were common, particularly autism among children, and depression in adults. Most frequent first-/second-line treatments were methylphenidate (MPH; 81.6%) and lisdexamfetamine dimesylate (LDX; 46.0%), respectively. In the second-line, LDX was most frequently prescribed (46.0%), followed by MPH (34.9%), then atomoxetine (7.7%). Median treatment duration was longest for LDX (10.4 months), followed by amphetamine (9.1 months).

Conclusion:

This nationwide registry study provides real-life insights into the current epidemiology of ADHD and the changing treatment landscape for patients in Sweden.

Keywords

ADHD prevalence psychiatric comorbidity Sweden treatment

Get full access to this article

View all access options for this article.

References

Ahnemark

Di Schiena

Fredman

A. C.

Medin

Soderling

J. K.

Ginsberg

(2018). Health-related quality of life and burden of illness in adults with newly diagnosed attention-deficit/hyperactivity disorder in Sweden. BMC Psychiatry, 18(1), 223.

Bachmann

C. J.

Wijlaars

L. P.

Kalverdijk

L. J.

Burcu

Glaeske

Schuiling-Veninga

C. C. M.

Hoffmann

Aagaard

Zito

J. M.

(2017). Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012. European Neuropsychopharmacology, 27(5), 484–493.

Biederman

DiSalvo

Green

Woodworth

K. Y.

Gilfix

Law

Gabrieli

Faraone

S. V.

(2021). Rates of switching stimulants in consecutively referred medication naive adults with ADHD. Acta Psychiatrica Scandinavica, 144(6), 626–634.

Electronic Medicines Compendium. (2020). Dexamfetamine sulfate summary of product characteristics. Retrieved August 22, 2022, from https://www.medicines.org.uk/emc/product/11004/smpc#gref

Electronic Medicines Compendium. (2021). Strattera summary of product characteristics. Retrieved August 22, 2022, from https://www.medicines.org.uk/emc/product/5531/smpc#gref

Electronic Medicines Compendium. (2023). Intuniv summary of product characteristics. Retrieved May 22, 2023, from https://www.medicines.org.uk/emc/product/5099/smpc#gref

Elliott

Johnston

Husereau

Kelly

S. E.

Eagles

Charach

Hsieh

S. C.

Bai

Hossain

Skidmore

Tsakonas

Chojecki

Mamdani

Wells

G. A.

(2020). Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. PLoS One, 15(10), e0240584.

European Observatory on Health Systems and Policies. (2021). Sweden. Retrieved March 24, 2023, from https://eurohealthobservatory.who.int/countries/sweden

Faraone

S. V.

Banaschewski

Coghill

Zheng

Biederman

Bellgrove

M. A.

Newcorn

J. H.

Gignac

Al Saud

N. M.

Manor

Rohde

L. A.

Yang

Cortese

Almagor

Stein

M. A

Albatti

T. H.

Aljoudi

H. F.

Alqahtani

M. M. J.

Asherson

. . . Wang

(2021). The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews, 128, 789–818.

10.

Fitzgerald

Dalsgaard

Nordentoft

Erlangsen

(2019). Suicidal behaviour among persons with attention-deficit hyperactivity disorder. British Journal of Psychiatry, 215(4), 615–620.

11.

Giacobini

Medin

Ahnemark

Russo

L. J.

Carlqvist

(2018). Prevalence, patient characteristics, and pharmacological treatment of children, adolescents, and adults diagnosed with ADHD in Sweden. Journal of Attention Disorders, 22(1), 3–13.

12.

Hart

L. C.

Grosse

S. D.

Danielson

M. L.

Baum

R. A.

Kemper

A. R.

(2021). Changes in provider type and prescription refills among privately insured children and youth with ADHD. Journal of Attention Disorders, 25, 2028–2036.

13.

Kooij

J. J. S.

Bijlenga

Salerno

Jaeschke

Bitter

Balazs

Thome

Dom

Kasper

Nunes Filipe

Stes

Mohr

Leppämäki

Casas

Bobes

Mccarthy

J. M.

. . . Asherson

(2019). Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry, 56, 14–34.

14.

National Board of Health and Welfare. (2018). About the Swedish healthcare system.

15.

National Board of Health and Welfare. (2020). The national patient register, Stockholm, Sweden. Retrieved May 19, 2022, from https://www.socialstyrelsen.se/en/about-us/healthcare-for-visitors-to-sweden/about-the-swedish-healthcare-system/

16.

Polanczyk

G. V.

Willcutt

E. G.

Salum

G. A.

Kieling

Rohde

L. A.

(2014). ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis. International Journal of Epidemiology, 43(2), 434–442.

17.

Polyzoi

Ahnemark

Medin

Ginsberg

(2018). Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden: A longitudinal population-based register study. Neuropsychiatric Disease and Treatment, 14, 1149–1161.

18.

Posner

Polanczyk

G. V.

Sonuga-Barke

(2020). Attention-deficit hyperactivity disorder. The Lancet, 395(10222), 450–462.

19.

Pottegard

Bjerregaard

B. K.

Kortegaard

L. S.

Zoega

(2015). Early discontinuation of attention-deficit/hyperactivity disorder drug treatment: A Danish nationwide drug utilization study. Basic & Clinical Pharmacology & Toxicology, 116(4), 349–353.

20.

Price

Newlove-Delgado

Eke

Paul

Young

Ford

Janssens

(2019). In transition with ADHD: The role of information, in facilitating or impeding young people’s transition into adult services. BMC Psychiatry, 19(1), 404.

21.

Raman

S. R.

Man

K. K. C.

Bahmanyar

Berard

Bilder

Boukhris

Bushnell

Crystal

Furu

KaoYang

Y. H.

Karlstad

Ø.

Kieler

Kubota

Lai

E. C.

Martikainen

J. E.

Maura

Moore

Montero

Nakamura

. . . Wong

I. C. K.

(2018). Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases. The Lancet Psychiatry, 5(10), 824–835.

22.

Rydell

Lundstrom

Gillberg

Lichtenstein

Larsson

(2018). Has the attention deficit hyperactivity disorder phenotype become more common in children between 2004 and 2014? Trends over 10 years from a Swedish general population sample. Journal of Child Psychology and Psychiatry, 59(8), 863–871.

23.

Sibley

M. H.

Swanson

J. M.

Arnold

L. E.

Hechtman

L. T.

Owens

E. B.

Stehli

Abikoff

Hinshaw

S. P.

Molina

B. S. G.

Mitchell

J. T.

Jensen

P. S.

Howard

A. L.

Lakes

K. D.

Pelham

W. E.

; MTA Cooperative Group. (2017). Defining ADHD symptom persistence in adulthood: Optimizing sensitivity and specificity. Journal of Child Psychology and Psychiatry, 58(6), 655–662.

24.

Song

Dieckmann

N. F.

Nigg

J. T.

(2019). Addressing discrepancies between ADHD prevalence and case identification estimates among U.S. children utilizing NSCH 2007-2012. Journal of Attention Disorders, 23(14), 1691–1702.

25.

Statistics Sweden. (2021). Population 1 November by region, age and sex. Year 2002-2021. Retrieved August 22, 2022, from https://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__BE0101A/FolkmangdNov/?rxid=8c7f8519-6a04-4f22-ba14-8b4e4fd4329b

26.

Swedish Institute. (2022). Healthcare in Sweden. Retrieved March 24, 2023, from https://sweden.se/life/society/healthcare-in-sweden

27.

Swedish Medical Products Agency. (2016). Medicines for ADHD – treatment recommendation. Retrieved August 22, 2022, from https://www.lakemedelsverket.se/sv/behandling-och-forskrivning/behandlingsrekommendationer/sok-behandlingsrekommendationer/lakemedel-vid-adhd—behandlingsrekommendation

28.

Thomas

Sanders

Doust

Beller

Glasziou

(2015). Prevalence of attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. Pediatrics, 135(4), e994–e1001.

29.

Wallerstedt

S. M.

Wettermark

Hoffmann

(2016). The first decade with the Swedish prescribed drug register: A systematic review of the output in the scientific literature. Basic & Clinical Pharmacology & Toxicology, 119(5), 464–469.

30.

Warrer

Thomsen

P. H.

Dalsgaard

Hansen

E. H.

Aagaard

Wallach Kildemoes

Rasmussen

H. B.

(2016). Switch in therapy from methylphenidate to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: An analysis of patient records. Journal of Child and Adolescent Psychopharmacology, 26(4), 354–361.

31.

Wolraich

M. L.

Chan

Froehlich

Lynch

R. L.

Bax

Redwine

S. T.

Ihyembe

Hagan

J. F.

(2019). ADHD diagnosis and treatment guidelines: A historical perspective. Pediatrics, 144(4), e20191682.

32.

World Health Organization. (2010). International statistical classification of diseases and related health problems – 10th Revision, Swedish modification. Retrieved August 25, 2022, from http://icd.internetmedicin.se/diagnos

33.

World Health Organization. (2022). Guidelines for ATC classification and DDD assignment. Retrieved May 19, 2022, from https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.06 MB

Epidemiology,Treatment Patterns,Comorbidities,and Concomitant Medication in Patients with ADHD in Sweden: A Registry-Based Study (2018–2021)

Abstract

Objective:

Method:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material